Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy.

Autor: Ma TM; Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA., Lilleby O; Faculty of Medicine, University of Copenhagen, 2200 Copenhagen, Denmark., Lilleby WA; Department of Oncology, Oslo University Hospital, 0424 Oslo, Norway., Kishan AU; Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA.; Department of Urology, University of California, Los Angeles, CA 90095, USA.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2020 Dec 02; Vol. 12 (12). Date of Electronic Publication: 2020 Dec 02.
DOI: 10.3390/cancers12123606
Abstrakt: Prostate cancer (PCa) is the most common noncutaneous solid organ malignancy among men worldwide. Radiation therapy is a standard of care treatment option that has historically been delivered in the form of small daily doses of radiation over the span of multiple weeks. PCa appears to have a unique sensitivity to higher doses of radiation per fraction, rendering it susceptible to abbreviated forms of treatment. Stereotactic body radiation therapy (SBRT) and high-dose-rate brachytherapy (HDRBT) are both modern radiation modalities that allow the precise delivery of ablative doses of radiation to the prostate while maximally sparing sensitive surrounding normal structures. In this review, we highlight the evidence regarding the radiobiology, oncological outcomes, toxicity and dose/fractionation schemes of SBRT and HDRBT monotherapy in men with low-and intermediate-risk PCa.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje